Health
Novo’s Ozempic, Wegovy Targeted for Medicare Price Cuts
- Pfizer’s top-selling breast cancer drug Ibrance also on list
- Drugmakers plan to ask Trump administration to pause talks
This article is for subscribers only.
The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.
Novo’s treatments for obesity and diabetes headline the government’s list of medicines that will be subject to price negotiations over the next year as part of a Biden administration effort to reduce drug costs for the Medicare health program for seniors.